Richter-Helm / Gedeon Richter Biologics (Mammalian DP complement)

Budapest, Hungary
Monoclonal Antibody Recombinant Protein Biosimilars Fill-Finish Mammalian Cell Culture
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (1) ✓ EMA GMP (9) ○ MHRA GMP

Quick Facts: Richter-Helm / Gedeon Richter Biologics (Mammalian DP complement)

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Budapest, Hungary
Modalities
Monoclonal Antibody, Recombinant Protein, Biosimilars, Fill-Finish, Mammalian Cell Culture
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Richter-Helm / Gedeon Richter Biologics (Mammalian DP complement)

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
EMA GMP Certificates9 on record
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs no verified data
Sponsorsno verified data
ModalitiesMonoclonal Antibody, Recombinant Protein, Biosimilars, Fill-Finish, Mammalian Cell Culture
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press1 articles
Broad modality coverage (5 modalities)

Richter-Helm / Gedeon Richter Biologics (Mammalian DP complement) EMA GMP Compliance 9 certificates

2025-11
2025-11
2025-02
2025-02
2022-06
2022-06
2022-06
2022-06
2017-06
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
DE_NI_02_GMP_2025_0058 Richter BioLogics GmbH Germany 2025-11-26 COMPLIANT
DE_NI_02_GMP_2025_0057 Richter BioLogics GmbH Germany 2025-11-26 COMPLIANT
DE_SH_01_GMP_2025_0041 Richter BioLogics GmbH Germany 2025-02-05 COMPLIANT
DE_SH_01_GMP_2025_0040 Richter BioLogics GmbH Germany 2025-02-05 COMPLIANT
DE_SH_01_GMP_2022_0044 Richter-Helm BioLogics GmbH & Co. KG Germany 2022-06-30 COMPLIANT
DE_SH_01_GMP_2024_0044 Richter-Helm BioLogics GmbH & Co. KG Germany 2022-06-30 COMPLIANT
DE_SH_01_GMP_2024_0043 Richter-Helm BioLogics GmbH & Co. KG Germany 2022-06-30 COMPLIANT
DE_SH_01_GMP_2022_0043 Richter-Helm BioLogics GmbH & Co. KG Germany 2022-06-30 COMPLIANT
DE_SH_01_GMP_2017_1032 Richter-Helm BioLogics GmbH & Co. KG Germany 2017-06-29 COMPLIANT
Source: EMA EudraGMDP · Retrieved Jul 11, 2026

Recent News 1 articles

general 2026-04-07
Gedeon Richter : GM - Proposals - marketscreener.com
Gedeon Richter : GM - Proposals  marketscreener.com

Frequently Asked Questions About Richter-Helm / Gedeon Richter Biologics (Mammalian DP complement)

Does Richter-Helm / Gedeon Richter Biologics (Mammalian DP complement) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 9 EMA GMP certificates for Richter-Helm / Gedeon Richter Biologics (Mammalian DP complement).
What is Richter-Helm / Gedeon Richter Biologics (Mammalian DP complement)'s CDMO Signal Score?
Richter-Helm / Gedeon Richter Biologics (Mammalian DP complement) has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Richter-Helm / Gedeon Richter Biologics (Mammalian DP complement) for a manufacturing program?
Use the free AI matchmaker to compare Richter-Helm / Gedeon Richter Biologics (Mammalian DP complement) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Recombinant Protein CDMOs →

Similar CDMOs

Catalent
Bagsværd, Denmark (operating under Novo Holdings; Bloomington, IN is primary fill-finish site)
Signal Score: 76.5
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
Signal Score: 75.1
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Mabion S.A.
Konstantynów Łódźki, Poland
Monoclonal Antibody, Recombinant Protein, Biosimilars, Vaccine Antigens, ADC / PDC (analytics & development), Sterile Fill-Finish
EirGenix
Zhubei City, Hsinchu County, Taiwan
Monoclonal Antibody, Bispecific/Polyclonal Antibody, Recombinant Protein, ADC, Biosimilars, Plasmid DNA
Boehringer Ingelheim BioXcellence
Ingelheim am Rhein, Germany
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Antibody Fragments, Biosimilars, Biologics